HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
An efficient and specific liquid chromatography (LC)-based assay was developed to monitor the production of recombinant HIV-1 trimeric envelope glycoprotein (HIV Env trimer), a candidate vaccine for HIV-1 infection, in cell culture media to support scale-up process development.
|
31060952 |
2019 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Viral entry, which involves the interaction of the surface envelope glycoprotein, gp120, with the cellular receptor, CD4, is the first step of HIV-1 infection.
|
31424369 |
2019 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have promising utility in prevention and treatment of HIV-1 infection, and several are currently undergoing clinical trials.
|
31604961 |
2019 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pseudotyping of HIV-1 with Human T-Lymphotropic Virus 1 (HTLV-1) Envelope Glycoprotein during HIV-1-HTLV-1 Coinfection Facilitates Direct HIV-1 Infection of Female Genital Epithelial Cells: Implications for Sexual Transmission of HIV-1.
|
29624497 |
2018 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings have yielded novel insights into the critical role of the viral Env and tropism as a driver of pathogenesis and host control and have helped to identify new areas for targeted interventions in therapy and prevention of HIV-1 infection.
|
29173176 |
2018 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Host antibodies elicited during natural HIV-1 infection or by vaccination can potentially recognize the Env spike and block HIV-1 infection.
|
29618643 |
2018 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Small-molecule CD4-mimetic compounds inhibit HIV-1 infection by multiple mechanisms: (i) direct blockade of the interaction between the gp120 exterior envelope glycoprotein and CD4; (ii) premature triggering of conformational changes in the envelope glycoproteins, leading to irreversible inactivation; and (iii) exposure of cryptic epitopes to antibodies, allowing virus neutralization.
|
27881646 |
2017 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some antibodies that arise during natural HIV-1 infection bind to conserved regions on the virus envelope glycoprotein and potently neutralize the majority of diverse HIV-1 strains.
|
25631091 |
2015 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIV-1 envelope glycoprotein is reported to interact with α4β7, an integrin mediating the homing of lymphocytes to gut-associated lymphoid tissue, but the significance of α4β7 in HIV-1 infection remains controversial.
|
25527342 |
2014 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Broadly neutralizing antibodies (bNAbs) against HIV-1 are generated during HIV-1-infection but have not yet been elicited by immunization with recombinant forms of the viral envelope glycoprotein (Env; the target of anti-HIV-1 neutralizing antibodies).
|
24352455 |
2014 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the risk factors for intrafamilial transmission of HIV-1 infection through qualitative epidemiology following pol and env gene sequencing and phylogenetic analysis.
|
22918554 |
2013 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin related (DC-SIGNR) can bind to the human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein and is thus important for the host-pathogen interaction in HIV-1 infection.
|
22957026 |
2012 |
HIV-1 infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection.
|
19913863 |
2010 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficient human immunodeficiency virus (HIV)-1 infection depends on multiple interactions between the viral gp41/gp120 envelope (Env) proteins and cell surface receptors.
|
16148047 |
2005 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
An objective of the first efficacy trial of a candidate vaccine containing recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein 120 (rgp120) antigens was to assess correlations between antibody responses to rgp120 and the incidence of HIV-1 infection.
|
15688279 |
2005 |
HIV-1 infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analysed three host response and viral characteristics were associated with recent HIV-1 infection: rapidly increasing EIA optical density (OD) values, genetically homogeneous env gene quasispecies, and putative non-syncytium inducing env V3 loop sequences.
|
11741169 |
2002 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results identify a region of CCR5 that is necessary for the physical association of the gp120 envelope glycoprotein with CCR5 and for HIV-1 infection.
|
9445013 |
1998 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
This relative resistance to HIV-1 infection did not extend to T cell line-adapted or syncytium-inducing (SI) primary viral isolates, was restricted by the envelope glycoprotein, and was associated with an increased production of the C-C chemokines RANTES, MIP-1alpha, and MIP-1beta.
|
9581891 |
1998 |
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the development of chimeric simian-human immunodeficiency virus (SHIV)-infected macaques as a model for assessing novel human immunodeficiency virus type I (HIV-1) envelope glycoprotein (Env)-based vaccine strategies for preventing HIV-1 infection in man, it will be important to determine HIV-1 Env-specific cytotoxic T-lymphocyte (CTL) responses in vaccinated and virus-infected monkeys.
|
8794394 |
1996 |